Medtech sector to benefit from improved utilization volumes in Q1 - Credit Suisse

NuVasive

09/04/2021 12:34

** Credit Suisse says overall utilization volumes in the
United States have improved throughout Q1, favoring U.S.-focused
small-to-mid cap cos in the medtech sector 
    ** Says surging COVID-19 infections and slower vaccine
rollouts across Europe have hit volumes across the continent,
while key Asian markets remain on track to deliver continued
improvements in volumes and utilization
    ** Stryker Corp  SYK.N , Globus Medical Inc  GMED.N ,
NuVasive Inc  NUVA.O , Integra Lifesciences Holding Corp
 IART.O  and Zimmer Biomet Holding  ZBH.N  best-positioned to
benefit from these near-term trends
    ** Brokerage says conviction on Edwards Lifesciences  EW.N  
and SYK remains high and recommends owning these stocks
    ** COVID-19 testing revenues from Abbott Laboratories
 ABT.N  to contribute to 2021 outlook and drive the stock
higher- CS
    ** Says Boston Scientific Corp  BSX.N  has a solid
opportunity to beat Q1 estimates
    ** Brokerage remains concerned over ZBH's ability to defend
its U.S. knee, hip and shoulder businesses from SYK, which could
have negative implications for growth, cash flows and equity
performance
    ** Expects digital health technologies in medtech to
continue to capture increasing interest and strategic
importance; SYK, Medtronic PLC  MDT.N , GMED and importantly
Johnson & Johnson  JNJ.N  best-positioned
    ** EW, SYK and GMED to deliver more durable above-market
growth and value creation in 2H21 and 2022

 (Reporting by Trisha Roy in Bengaluru)
 ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6182 3635;))